Open-label, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris
Authors:
Open Access
- 1 August 2020
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 83 (2) , 477-485
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial AcneJAMA Dermatology, 2020
- Androgens and androgen receptor action in skin and hair folliclesMolecular and Cellular Endocrinology, 2018
- Adult-onset acne: prevalence, impact, and management challengesClinical, Cosmetic and Investigational Dermatology, 2018
- Hormonal treatment of acne vulgaris: an updateClinical, Cosmetic and Investigational Dermatology, 2016
- Guidelines of care for the management of acne vulgarisJournal of the American Academy of Dermatology, 2016
- Acne vulgarisNature Reviews Disease Primers, 2015
- A full conformational characterization of antiandrogen cortexolone-17α-propionate and related compounds through theoretical calculations and nuclear magnetic resonance spectroscopyMedChemComm, 2014